UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  FORM 10-Q/A (AMENDMENT NO. 1)  [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________ Commission File Number: 000-53213  SINOCOM PHARMACEUTICAL, INC (Exact name of registrant as specified in its charter) Nevada26-1188540(State or other jurisdiction of incorporation)(IRS Employer Identification Number)Room 3, 21/F, Far East Consortium Building
121 Des Voeux Road
Central, Hong Kong(Address of principal executive offices)011-852-2159-7863(Registrants telephone number, including area code)  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  [ X ] Yes   [ ] No  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.  Large accelerated filer [ ]Accelerated filer [ ]Non-accelerated filer [X]  (Do not check if a smaller reporting company)Smaller reporting company [ ]  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    [   ] Yes   [ X ] No  As of March 31, 2010, the Issuer had 71,416,660 shares of common stock issued and outstanding.   1   Explanatory Note Sinocom Pharmaceutical, Inc. (the Company) is filing this Amendment No. 1 (the Amendment or Form 10-Q/A) to the Companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 filed with the Securities and Exchange Commission on May 19, 2010 (the Original Filing) to amend and restate our interim unaudited financial statements for the period ended March 31, 2010 and the related notes thereto, in light of changes in the Consolidated Statement of Stockholders Equity related to a change in the application of accounting for business combination from the pooling-of-interest method to the purchase method for the 2006 acquisition of Anqing Zhongxi Yao Ltd.  For a more detailed description of the Restatement, see Note 2 Restatement of the Notes to Consolidated Financial Statements. This Form 10-Q/A amends and restates "Item 1 Financial Statements" and Item 4."Controls and Procedures" of Part I of the Original Filing, as amended, in each case, solely as a result of, and to reflect, the Restatement.  Pursuant to the rules of the SEC, Item 6 of Part II of the Original Filing has been amended to contain currently-dated certifications from our principal executive officer and principal financial officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. The certifications of our principal executive officer and our principal financial officer are attached to this form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2.  Except for the foregoing amended information, this Form 10-Q/A continues to describe conditions as of the date of the Original Filing, and we have not updated the disclosures contained herein to reflect events that have occurred subsequent to that date.  Other events occurring after the date of the Original Filing or other information necessary to reflect subsequent events have been disclosed in reports filed with the SEC subsequent to the Original Filing.   PART I-FINANCIAL INFORMATION  ITEM 1 FINANCIAL STATEMENTS.   The consolidated financial statements of Sinocom Pharmaceutical, Inc. (the "Company" or the Registrant), a Nevada corporation, included herein were prepared, without audit, pursuant to rules and regulations of the Securities and Exchange Commission.  Because certain information and notes normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America were condensed or omitted pursuant to such rules and regulations, these financial statements should be read in conjunction with the Companys audited consolidated financial statements for the fiscal years ended December 31, 2009 and 2008, and notes thereto, included in the Company's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2009, filed with the Securities and Exchange Commission on September 29, 2010.                2    SINOCOM PHARMACEUTICAL, INC CONSOLIDATED FINANCIAL STATEMENTS PERIOD ENDED MARCH 31, 2010  INDEX TO FINANCIAL STATEMENTS  PageConsolidated Balance Sheets(Unaudited)4Consolidated Statements of Income (Unaudited)5Consolidated Statements of Cash Flows (Unaudited)6Notes to Unaudited Financial Statements7-9   3     SINOCOM PHARMACEUTICAL, INC.CONSOLIDATED BALANCE SHEETSAS OF MARCH 31, 2010 AND DECEMBER 31, 2009
(UNAUDITED)ASSETS3/31/201012/31/2009(restated)(restated)Current AssetsCash and cash equivalents$23,892,938$34,363,124Accounts receivable19,642,92822,488,263Inventory2,416,2012,120,516Trade deposits4,834,541-Prepaid expenses and other receivables144,497180,933Total Current Assets50,931,10559,152,836Land use right2,970,974-Prepaid lease3,932,0871,366,234Deposit for construction2,856,775-Property and equipment, net677,079613,891Total Assets$61,368,020$61,132,961LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable$10,458,333$14,537,732Due to related parties117,839-Accrued expenses and other payables1,037,3901,715,759Income tax payable2,075,3982,220,501Total Current Liabilities13,688,96018,473,992Stockholders' EquityCommon stock, par value $.001; 150,000,000 shares authorized;  71,416,660 shares issued and outstanding71,41771,417Preferred stock, par value $.001; 20,000,000 shares authorized;15,847,099 shares issued and outstanding15,84715,847Additional paid in capital15,113,31315,490,448Statutory reserves5,677,0415,677,041Other comprehensive income4,924,5334,905,832Retained earnings21,876,90916,498,384Total Stockholders' Equity47,679,06042,658,969Total Liabilities and Stockholders' Equity$61,368,020$61,132,961The accompanying notes are an integral part of these consolidated financial statements.   4     SINOCOM PHARMACEUTICAL, INC.
CONSOLIDATED STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2010 and 2009
(UNAUDITED)20102009Sales, net$24,896,351$19,669,619Cost of sales16,169,01312,939,180Gross profit8,727,3386,730,439Selling, general and administrative expenses1,163,890728,888Income from operations7,563,4486,001,551Other (income) expenseNon-operating income(69,047)2,339Interest (income)(6,187)(8,620)Total other (income) expense(75,234)(6,281)Income before income taxes7,638,6826,007,832Provision for income taxes2,075,2251,589,782Net income$5,563,457$4,418,050Dividend on series A preferred stock(184,932)-Net income (loss) available to common shareholders$5,378,525$4,418,050Net income per common shareBasic$0.075$0.064Diluted$0.064$0.064Weighted average common shares outstandingBasic71,416,66068,988,493Diluted87,263,75968,988,493The accompanying notes are an integral part of these consolidated financial statements.   5    SINOCOM PHARMACEUTICAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009
(UNAUDITED)20102009CASH FLOWS FROM OPERATING ACTIVITIESNet Income$5,563,457$4,418,050Adjustments to reconcile net income to net cashprovided by operating activities:Depreciation and amortization154,96623,611Loss on disposal of property and equipment3,161-(Increase) / decrease in current assets:Accounts receivables2,845,335(2,331,826)Inventory(295,685)1,470,850Prepaid expense and other receivables36,436(1,794,334)Trade deposits(4,834,541)-Increase / (decrease) in current liabilities:Accounts payable(4,079,399)5,432,125Accrued expenses and other payables(678,369)741Due to related parties117,8381,417Income taxes payable(145,103)348,711Total Adjustments(6,875,361)3,151,295Net cash provided/(used) by operating activities(1,311,904)7,569,345CASH FLOWS FROM INVESTING ACTIVITIESPurchase of property and equipment(83,144)-Payment to acquire land use right(2,985,905)-Prepaid lease(2,689,091)-Deposit paid for construction(2,856,775)-Net cash used by investing activities(8,614,915)-CASH FLOWS FROM FINANCING ACTIVITIESIssuance cost of preferred stock paid(377,135)Preferred stock dividend paid(184,932)-Net cash  used by financing activities(562,067)-Effect of exchange rate changes on cash and cash equivalents18,70018,098Net change in cash and cash equivalents(10,470,186)7,587,443Cash and cash equivalents, beginning balance34,363,1245,302,591Cash and cash equivalents, ending balance$23,892,938$12,890,034SUPPLEMENTAL DISCLOSURES:Cash paid during the period for:Income tax2,220,328$1,241,071    6   SINOCOM PHARMACEUTICAL, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2010 (Unaudited)   Note 1 - ORGANIZATION  Sinocom Pharmaceutical, Inc. (Sinocom or Company) was formed on September 13, 2007 in the State of Nevada. The Company was originally incorporated as Tiger Acquisitions, Inc. and changed its name to Sinocom on February 26, 2009.  Through a share exchange, Rolling Rhine Holdings, Ltd (Rolling Rhine) and its wholly-owned subsidiaries, China Zhongxi Yao Group Ltd and Anqing Zhongxi Yao Ltd (Anqing Zhongxi Yao), became wholly-owned subsidiaries of the Company. Rolling Rhine was incorporated in December 2007, under the laws of the British Virgin Islands as a holding company for the purposes of owning 100% of China Zhongxi Yao Group Ltd. China Zhongxi Yao Group Limited was incorporated in July 2008, under the laws of Hong Kong company, for the purpose of owning 100% of the equity interest of Anqing Zhongxi Yao. Anqing Zhongxi Yao, formed in December 1997, was organized under the laws of the Peoples Republic of China (PRC) and was owned by a number of individuals until December 13, 2005 when it was acquired by a company, which was under the common control of Rolling Rhine and China Zhongxi Yao.  Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  Basis of Presentation  The accompanying condensed consolidated financial statements have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments, consisting of only those of a normal recurring nature, considered necessary for a fair presentation of the financial position and interim results of the Company as of and for the periods presented, have been included.  Interim results are not necessarily indicative of results to be expected for a full year.  These financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  The financial information included herein should be read in conjunction with the Companys consolidated financial statements and related notes in its 2009 Annual Report on Form 10-K/A  filed on September 29, 2010.   Note 3 - RESTATEMENT  When the Company accounted for the 2006 acquisition of Anqing Zhongxi Yao from the former shareholders, the Company determined that pooling-of-interest method was appropriate. Recently, in preparing the latest Form 10-Q for June 30, 2010, the Company revisited the accounting treatment the acquisition of Anqing Zhongxi Yao with its external consultant. After due consideration, the Company determined that the purchase method should be applied in accounting for the acquisition of Anqing Zhongxi Yao. The use of purchase method has resulted in significant changes to several components in the statement of stockholders equity as of January 1, 2006, and also changes to the balances carried forward in the subsequent periods. There is, however, no effect on the statements of cash flows, statements of income or total assets as presented in the financial statements the Company previously filed in its Form 10-K.  7    The restatement adjustments are detailed as follows:


|                                                 |   |              |   |                 |   |                            |   |                            |   |                    |   |                   |   |                           
|------------------------------------------------ | - | ------------ | - | --------------- | - | -------------------------- | - | -------------------------- | - | ------------------ | - | ----------------- | - | --------------------------
|                                                 |   | Common Stock |   | Preferred Stock |   | Additional Paid in Capital |   | Other Comprehensive Income |   | Statutory Reserves |   | Retained Earnings |   | Total Stockholders' Equity
|                                                 |   |              |   |                 |   |                            |   |                            |   |                    |   |                   |   |                           
|Balance January 1,  2010, as reported previously | $ | 71,417       | $ | 15,847          | $ | 13,856,076                 | $ | 4,903,784                  | $ | 7,617,885          | $ | 16,193,960        | $ | 42,658,969                
|Adjustments                                      |   | 0            |   | 0               |   | 1,634,372                  |   | 2,048                      |   | (1,940,844)        |   | 304,424           |   | 0                         
|Balance as January 1, 2010, restated             | $ | 71,417       | $ | 15,847          | $ | 15,490,448                 | $ | 4,905,832                  | $ | 5,677,041          | $ | 16,498,384        | $ | 42,658,969                
|                                                 |   |              |   |                 |   |                            |   |                            |   |                    |   |                   |   |                           

Note 4  INVENTORIES 3/31/201012/31/2009Finished goods$2,416,201$2,120,516   Note 5 – TRADE DEPOSITS  Trade deposits represents amount held by pharmacy agencies for distribution rights and are refundable upon expiry of the distribution agreements.   Note 6 – LAND USE RIGHT  The land use right consisted of the following: 3/31/201012/31/2009Land lease$2,985,873$-Less: Accumulated amortization(14,899)-$2,970,974$- In January 2010, a subsidiary of the Company operating in Anqing, the PRC acquired a land use right, which granted the Company a right to use a piece of land for a period of 50 years commencing on January 1, 2010. Amortization expense was $14,899 for the three months ended March 31, 2010.   Note 7  DEPOSIT FOR CONSTRUCTION  The Company entered into an agreement with a developer and paid a deposit for the construction of distributor centre.   Note 8  DUE TO RELATED PARTY  The amount was due to the Companys chief executive officer.  The amount was unsecured, interest-free and repayable on demand.   8   Note 9  COMMITMENTS & CONTINGENCIES  The Company leases facilities under operating leases, extending through January 2018. For the period ended March 31, 2010 and 2009, total lease expenses were $167,400 and $86,470, respectively.  The future minimum obligations under these agreements are as follows:  Year 1     $   478,463 Year 2     $   478,463 Year 3     $   478,463 Year 4     $   478,463 Year 5     $   478,463 Thereafter   $   1,472,499  In 2009, the Company has entered into a 50-year land lease for acquisition of unprocessed herbs cultivated through April 30, 2059. Terms of lease call for 5 payments at the beginning of each ten year period.  The total minimum obligation under the lease total $7,228,825 with second payment due May 1, 2019. Any breach by either party to the lease calls for a penalty payment of approximately $146,283 plus any economic loss incurred. The first payment has been capitalized and is being amortized over ten years. Amortization expense for the three months ended March 31, 2010 and 2009 totaled $36,622 and $0, respectively.  ITEM 2 MANAGEMENTS DISCUSSIONS AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.  SPECIAL NOTE OF CAUTION REGARDING FORWARD-LOOKING STATEMENTS   CERTAIN STATEMENTS IN THIS REPORT, INCLUDING STATEMENTS IN THE FOLLOWING DISCUSSION, ARE WHAT ARE KNOWN AS "FORWARD LOOKING STATEMENTS", WHICH ARE BASICALLY STATEMENTS ABOUT THE FUTURE. FOR THAT REASON, THESE STATEMENTS INVOLVE RISK AND UNCERTAINTY SINCE NO ONE CAN ACCURATELY PREDICT THE FUTURE. WORDS SUCH AS "PLANS," "INTENDS," "WILL," "HOPES," "SEEKS," "ANTICIPATES," "EXPECTS "AND THE LIKE OFTEN IDENTIFY SUCH FORWARD LOOKING STATEMENTS, BUT ARE NOT THE ONLY INDICATION THAT A STATEMENT IS A FORWARD LOOKING STATEMENT. SUCH FORWARD LOOKING STATEMENTS INCLUDE STATEMENTS CONCERNING OUR PLANS AND OBJECTIVES WITH RESPECT TO THE PRESENT AND FUTURE OPERATIONS OF THE COMPANY, AND STATEMENTS WHICH EXPRESS OR IMPLY THAT SUCH PRESENT AND FUTURE OPERATIONS WILL OR MAY PRODUCE REVENUES, INCOME OR PROFITS. NUMEROUS FACTORS AND FUTURE EVENTS COULD CAUSE THE COMPANY TO CHANGE SUCH PLANS AND OBJECTIVES OR FAIL TO SUCCESSFULLY IMPLEMENT SUCH PLANS OR ACHIEVE SUCH OBJECTIVES, OR CAUSE SUCH PRESENT AND FUTURE OPERATIONS TO FAIL TO PRODUCE REVENUES, INCOME OR PROFITS. THEREFORE, THE READER IS ADVISED THAT THE FOLLOWING DISCUSSION SHOULD BE CONSIDERED IN LIGHT OF THE DISCUSSION OF RISKS AND OTHER FACTORS CONTAINED IN THIS REPORT ON FORM 10-Q AND IN THE COMPANY'S OTHER FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. NO STATEMENTS CONTAINED IN THE FOLLOWING DISCUSSION SHOULD BE CONSTRUED AS A GUARANTEE OR ASSURANCE OF FUTURE PERFORMANCE OR FUTURE RESULTS.   9   Overview  Sinocom Pharmaceutical, Inc (sometimes hereinafter referred to as We,  Us, Our, or the Company) is a Chinese pharmaceutical company engaged in the two complimentary businesses of wholesale distribution of pharmaceuticals and medical supplies, and cultivation and sale of natural herbs. The operations involving wholesale distribution of pharmaceuticals and medical supplies were commenced in 1986 as a state-owned enterprise by a predecessor of the Company. The Company commenced operations in 1997 when the state-owned predecessor company was privatized.  In 2009, the Company distributed a portfolio of over 5,446 types of western pharmaceuticals, medical supplies and processed Chinese herbs, to over 4,166 customers including hospitals, clinics, drug stores and sub-distributors covering five provinces in southeastern China.  The operations relating to cultivation of natural herbs were commenced by the Company in 2004. They currently involve seven main species of herbs which are cultivated by over 700 farmers on a plantation base of approximately 15.1 million square meters located primarily in the Da Bie mountain region of Anhui province, PRC.  Our business operations are based in Anqing, Anhui Province, PRC, and all operations are currently conducted through our wholly-owned subsidiary, Anqing Zhongxi Yao Ltd., a PRC corporation.   History  The Company was incorporated in the State of Nevada on September 13, 2007, under the name Tiger Acquisitions, Inc.  It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. On February 26, 2009, the Company changed its name to Sinocom Pharmaceutical, Inc.  On February 20, 2009, the Company completed a share exchange transaction with Rolling Rhine Holdings, Ltd., a British Virgin Islands corporation (Rolling Rhine), pursuant to which the shareholders of Rolling Rhine transferred 300,000 shares of Rolling Rhine, representing all of the issued and outstanding shares of common stock in Rolling Rhine, to the Company in exchange for the issuance of an aggregate of 67,131,660 shares of the Companys common stock.  As a result of the share exchange transaction, Rolling Rhine Holdings, Ltd., and its subsidiaries, China Zhongxi Yao Group Limited, and Anqing Zhongxi Yao, Ltd., became wholly-owned subsidiaries of the Company.  Rolling Rhine was incorporated in December, 2007, under the laws of the British Virgin Islands, and China Zhongxi was incorporated in December, 2007, under the laws of Hong Kong. China Zhongxi was formed for the purpose of owning 100% of the capital stock of Anqing Zhongxi, and Rolling Rhine was formed as a holding company for the purposes of owning 100% of the capital stock of China Zhongxi.  Corporate Structure   The Chart below depicts the Companys current corporate structure.  The Company owns 100% of the capital stock of Rolling Rhine and has no other direct subsidiaries.  Rolling Rhine owns 100% of the capital stock of China Zhongxi and has no other direct subsidiaries. China Zhongxi owns 100% of the capital stock of Anqing Zhongxi and has no other subsidiaries.  10    Sinocom Pharmaceutical, Inc.
A Nevada Corporation ↓ 100% Rolling Rhine Holdings, Ltd.
A British Virgin Islands Corporation ↓ 100% China Zhongxi Yao Group Limited
A Hong Kong Corporation ↓ 100% Anqing Zhongxi Yao, Ltd,
A PRC Corporation    Results of Operation  Results of Operation for Sinocom Pharmaceutical, Inc., for the Three Months Ended March 31, 2010 Compared to the Three Months Ended March 31, 2009.  The following discussion and analysis provides information that we believe is relevant to an assessment and understanding of our results of operation and financial condition for the three month periods ended March 31, 2010 and 2009.  Our financial statements are stated in US Dollars and are prepared in accordance with generally accepted accounting principles of the United States (GAAP).  Revenue  Revenue for the three months ended March 31, 2010 was $24,896,351, as compared to revenue of $19,669,619 for the three months ended March 31, 2009, an increase of $5,226,732, or approximately 26.6%.  The increase in revenue was attributable to both the distribution of pharmaceutical products (for which revenues increased by $4,834,016, or approximately 38.4%, in the three months ended March 31, 2010 as compared to the same period in 2009), and to sales of cultivated natural herbs (for which revenue increased by $392,716, or approximately 5.5%, in the three months ended March 31, 2010, as compared to the same period of 2009).    The increase in revenue from sales of cultivated herbs is primarily attributable to the increasing size of our natural herbs plantation.  The increase in revenue from distribution of pharmaceutical products is primarily attributable to the higher sales and marketing effort and the results of PRC's 2009 RMB850 billion Health Reform Plan where major efforts are focused on improving medical care for the rural population (where our distribution business is).  Gross Profit  Cost of Sales increased $3,229,833, or approximately 25.0%, to $16,169,013 for the three months ended March 31, 2010, as compared to $12,939,180 for the three months ended March 31, 2009, primarily as a result of higher sales volume. Gross profit for the three months ended March 31, 2010, increased  $1,996,899, or approximately 29.7%, to $8,727,338 for the three months ended March 31, 2010, as compared to $6,730,439 for three months ended March 31, 2009. The increase in gross profit is attributable in part to the fact that gross margin from distribution of pharmaceutical products increased by $1,317,864, or approximately 45%, to $4,250,973 the three months ended March 31,  11   2010, as compared to $2,933,109 for three months ended March 31, 2009. Gross margin from sales of cultivated herbs increased by $679,035, or approximately 17.9%, to $4,476,365 for the three months ended March 31, 2010, as compared to $3,797,330 for the three months ended March 31, 2009.  Selling, General and Administrative Expenses  For the three months ended March 31, 2010, selling, general and administrative expenses were $1,163,890 as compared to $728,888 for the three months ended March 31, 2009. The increase of $435,002, or approximately 60.0%, was primarily attributable to higher sales promotional expenses.  Income From Operations  Income from operations increased $1,561,897, or approximately 26.0%, to $7,563,448 for the three months ended March 31, 2010, as compared to $6,001,551 for the three months ended March 31, 2009,  mainly due to higher distribution sales of pharmaceutical products,and increased cultivated herbs sales.  Net Income The Company recorded net income of $5,563,457 for the three months ended March 31, 2010, as compared to $4,418,050 for the three months ended March 31, 2009. The increase of $1,145,407, or approximately 25.9%, was mainly due to higher distribution sales of pharmaceutical products,and increased cultivated herbs sales.  Liquidity and Capital Resources    Total Current Assets & Total Assets  As of March 31, 2010, we had current and total assets of $50,931,105 and $61,368,020, respectively, as compared to current and total assets of $59,152,836 and $61,132,961, respectively, as of December 31, 2009.  The decrease in current assets from December 31, 2009 to March 31, 2010, of $8,221,731 and increase in total assets from December 31, 2009 to March 31, 2010, of $235,059 are primarily attributable to the Company's increased prepaid lease for cultivation of natural herbs and land rights for construction of 62,000 square metres of modern warehouses in Anqing.  Total Current Liabilities  As of March 31, 2010, we had total current liabilities of $13,688,960, as compared to total current liabilities of $18,473,992, as of December 31, 2009.  The decrease in total current liabilities of $4,785,032, or approximately 25.9%, is primarily attributable to lower accounts payable as a result of earlier payment to distribution suppliers in order to secure better terms. We have also placed $4,834,541 trade deposits in the arrangement.  Operating Activities  Net cash used by operating activities was $1,311,904 for the three months ended March 31, 2010, as compared net cash provided by operating activities of $7,569,345 for the three months ended March 31, 2009. The decrease of $8,881,249, or approximately 117.7%, was primarily the result of a decrease in accounts payable together with an increase in trade deposits, which were partially offset by a decrease in accounts receivable.   12   Investing Activities  Net cash used by investing activities was $8,614,915 for the three months ended March 31, 2010, as compared to nil for the three months ended March 31, 2009.  The increase was attributable to increased land use rights, prepaid lease and deposit for warehouse construction.   Financing Activities  Net cash used in financing activities was $562,067 for the three months ended March 31, 2010, as compared to nil for the three months ended March 31, 2009.  The increase of $562,067 was attributable to cost of issuing preferred stocks, and dividends paid to preferred stockholders.   Off Balance Sheet Arrangements  The Company does not have any off-balance sheet arrangements.  ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.  Inflation  Inflation has not had a material impact on our business.  Foreign Exchange Rate Risk  Although the conversion of the RMB is highly regulated in China, the value of the RMB against the value of the U.S. dollar (or any other currency) may fluctuate and be affected by, among other things, changes in Chinas political and economic conditions. Under the currency policy in effect in China today, the RMB is permitted to fluctuate in value within a narrow band against a basket of certain foreign currencies. China is currently under significant international pressures to liberalize this currency policy, and if such liberalization occurs, the value of the RMB could appreciate or depreciate against the U.S. dollar.  While our reporting currency is the U.S. dollar, to date all of our revenue and expenses and all of our assets are denominated in RMB.  As a result, we are exposed to foreign exchange risk because our revenues and results of operations may be affected by fluctuations in the exchange rate between the U.S. dollar and the RMB. If the RMB depreciates against the U.S. dollar, the value of our RMB revenues and assets as expressed in our U.S. dollar financial statements will decline. The fluctuations in the exchange rate would affect our financial results translated in U.S. dollar terms without giving effect to any underlying change in our business or results of operations.  For reporting purposes, all assets and liabilities were translated at the current exchange rate, stockholders equity are translated at the historical rates and income statement items are translated at the average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income as a component of shareholders equity.  Transaction gains and losses are reflected in the income statement.  ITEM 4 CONTROLS AND PROCEDURES.  Disclosure Controls and Procedures  The Securities and Exchange Commission defines the term disclosure controls and procedures to mean the   controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of  13   1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissions rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuers management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.  The Company maintains such a system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC's rules and forms and that information required to be disclosed is accumulated and communicated to principal executive and principal financial officers to allow timely decisions regarding disclosure.  As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures.  Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are designed to provide reasonable assurance of achieving the objectives of timely alerting them to material information required to be included in our periodic SEC reports and of ensuring that such information is recorded, processed, summarized and reported within the time periods specified.  Our chief executive officer and chief financial officer also concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report to provide reasonable assurance of the achievement of these objectives.  As reported in a filing on Form 8-K dated August 6, 2010, subsequent to the filing of our report on From 10-Q for the period ended March 31, 2010, we changed accountants and appointed BDO Limited as our principal independent accountant to audit our financial statements for the fiscal year ended December 31, 2010. We changed accountants solely in order to obtain BDO Limiteds greater experience in auditing the financial statements of global public companies.  In addition, because we desire to have only one accountant included in our prospective filings, we also engaged BDO Limited to re-audit our financial statements for the years ended December 31, 2007, 2008 and 2009.  In conjunction with re-audit of our financial statements from prior years, management determined that a restatement was required of our financial statements for the year ended December 31, 2009, included in our report on Form 10-K for the fiscal year ended December 31, 2009, and of our interim unaudited financial statements for the period ended March 31, 2010, included in our report on Form 10-Q for the period ended March 31, 2010. The restatement of our financial statements for the fiscal year ended December 31, 2009, was necessary in order to amend and restate our stockholders equity for the fiscal years ended December 31, 2009 and 2008, and the related notes thereto, in light of a change in the application of accounting for business combination from the pooling-of-interest method to the purchase method for the 2006 acquisition of Anqing Zhongxi Yao Ltd. The restatement of our interim unaudited financial statements for the period ended March 31, 2010, was necessary to reflect the effects of the December 31, 2009 restatement on our March 31, 2010 financial statements. As a result of the foregoing, management determined that a material weakness existed with respect to our reporting of complex non-routine transactions. This weakness was a result of our incorrect conclusion regarding the correct method of acquisition accounting to be used in conjunction with the 2006 acquisition of Anqing Zhongxi Yao Ltd.  As a result of the material weakness identified with respect to our reporting of complex, non-routine transactions, our chief executive officer and chief financial officer re-evaluated our disclosure controls and procedures and concluded that our disclosure controls and procedures were not adequate, as of the end of the period covered by this report, to ensure that the information required to be disclosed by us in our SEC reports was recorded, processed, summarized and reported within the time periods specified.   14   Subsequent to the filing of our report on Form 10-Q for the period ended March 31, 2010, to remediate the weakness in our disclosure controls and procedures, we hired third party consultants to assist us in identifying and analyzing complex non-routine transactions and with determining the appropriate accounting treatment for any such complex, non-routine transactions.  Changes in Internal Control over Financial Reporting  Our management revised its assessment of the effectiveness of our internal control over financial reporting as of December 31, 2009, originally included in our report on Form 10-K filed on March 31, 2010. Subsequent to filing, on May 19, 2010, of our report on Form 10-Q  for the period ended March 31, 2010, we identified errors in our 2009 financial statements and have restated those financial statements in a report on Form 10-K/A.  We have also restated our interim unaudited financial statements for the period ended March 31, 2010, in this report on Form 10-Q/A.  Management has concluded that these errors resulted from control deficiencies that represent material weakness in internal control over financial reporting.  As a result, management revised its assessment of the effectiveness of our internal control over financial reporting due to material weakness in our reporting of complex, non-routine transactions, and concluded that as of December 31, 2009, and as of March 31, 2010, our internal control over financial reporting was not effective.  Subsequent to filing of our report on Form 10-Q for the period ended March 31, 2010, to remediate the weakness in our internal controls over financial reporting, we hired third party consultants to assist us in identifying and analyzing complex non-routine transactions and determining the appropriate accounting treatment for any such complex non-routine transactions.   PART II-OTHER INFORMATION  ITEM 1 LEGAL PROCEEDINGS.  The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated. No director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than 5.0% of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.  ITEM 1A.  RISK FACTORS.  Not Applicable.  ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.  Not Applicable   ITEM 3. DEFAULTS UPON SENIOR SECURITIES.  None.  ITEM 4. (REMOVED AND RESERVED)  ITEM 5.  OTHER INFORMATION.  None.   15   ITEM 6. EXHIBITS.  a. The following exhibits are filed herewith:  31.1  Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* 31.2  Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* 32.1  Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* 32.2  Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* * filed herewith               SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  SINOCOM PHARMACEUTICAL, INC.  By:  /s/ XueXiang Ai, Chief Executive Officer  Date:  October 6, 2010   By:     /s/ Tuck Wing Pang, Chief Financial Officer   Date:  October 6, 2010   16